---

Colorectal Polyps: From Scratch to Pro Level

Sources: Schwartz's Principles of Surgery (11e), Sleisenger & Fordtran's GI and Liver Disease, Yamada's Textbook of Gastroenterology (7e), Bailey & Love's Short Practice of Surgery (28e), Robbins & Kumar Basic Pathology, Robbins Cotran & Kumar Pathologic Basis of Disease, Current Surgical Therapy (14e)

---

1. Definition and Basic Concept

• Approximately 90% of polyps detected at colonoscopy are mucosal in origin
• Of mucosal polyps, ~75% are adenomas
• 20-53% of average-risk persons over age 50 harbor at least one adenoma

---

2. Classification

---

3. Morphology: Pedunculated vs. Sessile

• Pedunculated: attached by a vascular stalk; most amenable to snare polypectomy
• Sessile: flat or broad-based; no stalk; greater technical challenge for resection
• Flat/depressed lesions: especially dangerous - sessile and depressed lesions have MORE malignant potential than pedunculated lesions of equivalent size

---

4. Adenomatous Polyps (Conventional Adenomas)

4.1 Epidemiology

• Most common polyp with malignant potential, representing 50-65% of all colonic polyps
• Found in up to 25% of persons over 50 in the US (Schwartz)
• Autopsy studies: nearly 50% of subjects had at least one adenoma
• Men have ~1.5x higher risk than age-matched women
• Prevalence rises steeply with age: ~1-5% in 30-39 years, 16% in 50-59 years, 25% by age 70-79

4.2 Histologic Types

• Most common: 65-85% of all adenomas (Current Surgical Therapy); 80-86% in Sleisenger
• Complex network of tubular, branching glands
• Glands do not extend beyond the muscularis mucosae
• Small, usually <1 cm; mild dysplasia predominates
• Risk of malignancy: ~5%

• 3-16% of all adenomas
• Long, finger-like projections (villi) extending from the stroma to the surface
• Large, often sessile; secretory - can cause watery diarrhea with electrolyte imbalance (McKittrick-Wheelock syndrome in extreme cases)
• Risk of malignancy: up to 40%
• ~60% of polyps >2 cm are villous

• 8-16% of adenomas; mixture of both patterns
• Risk of malignancy: ~22% (Schwartz)
• A polyp is classified as tubular if ≥80% tubular glands, villous if ≥80% villiform

4.3 Dysplasia

• Low-grade dysplasia (LGD): Nuclei basally located, hyperchromatic, slightly enlarged but uniform. Glands show branching and budding. Goblet cell mucin loss begins.
• High-grade dysplasia (HGD): (= former "severe dysplasia" / "carcinoma in situ") - Nuclear stratification, pleomorphism, prominent nucleoli, extreme glandular crowding, complete loss of goblet mucin. No metastatic potential as long as muscularis mucosae is intact.

4.4 Histology Images

---

5. The Adenoma-Carcinoma Sequence

5.1 Molecular Pathways

• Normal mucosa → hyperproliferative epithelium → early adenoma → intermediate adenoma → late adenoma → carcinoma
• Key mutations: APC loss (early) → KRAS mutation → SMAD4 loss → TP53 loss (late)
• Predominates in left-sided, non-mucinous CRC

• Defects in MMR genes (MLH1, MSH2, MSH6, PMS2)
• Accumulation of mutations in microsatellite regions at rates up to 1000x normal
• Right-sided predominance; mucinous histology; better prognosis
• Underlies Lynch syndrome (HNPCC) and ~10-15% sporadic CRC (via MLH1 methylation)

• BRAF mutation → KRAS mutation → CpG island methylator phenotype (CIMP) → MLH1 silencing by promoter methylation → carcinoma
• Sessile serrated lesions (SSLs) are the key precursor
• Right-sided; microsatellite unstable; mucinous

5.2 Timeline

• Mean age difference between adenoma and cancer: ~4-5 years for sporadic lesions
• Average dwell time from mild dysplasia to cancer: ~8 years; severe dysplasia to cancer: ~3.6 years
• Over a 10-year period, the risk that an adenoma-bearing person develops CRC is only ~2.5% (Sleisenger) - but this risk is dramatically higher for large or villous lesions

---

6. Serrated Polyps

6.1 Hyperplastic Polyps (HP)

• Most common serrated polyp (~75% of serrated lesions)
• Usually small (<5 mm), located in the rectosigmoid
• Serrated architecture limited to the upper crypt only; glands taper near base
• Prominent neuroendocrine cells; thickened collagen table
• Three subtypes: Microvesicular (most common), goblet cell-rich, mucin-poor (no clinical significance to subtype in daily practice)
• Traditionally benign with no malignant potential
• Exception: large HPs (>1 cm), right-sided location, >20 HPs, or family history of CRC - these carry elevated risk

6.2 Sessile Serrated Lesion (SSL) / Sessile Serrated Adenoma (SSA)

• Also called SSA/P (sessile serrated adenoma/polyp); 2019 WHO recommends "SSL"
• ~9% of all colonic polyps; 15-25% of serrated polyps (Yamada)
• Predominantly right colon - broad-based, may reach several cm, subtle endoscopic appearance (color similar to adjacent mucosa, may look like a thickened fold)
• Histology: serrated architecture extending to the deep crypts, papillary invaginations, dilated and horizontally oriented crypt bases (L-shaped or boot-shaped crypts), few neuroendocrine cells, thin collagen table
• Key molecular events: BRAF mutation → CIMP → MLH1 methylation → CRC
• Loss of MLH1 occurs at the point of cytologic dysplasia; aberrant nuclear β-catenin labeling in SSLs with acquired conventional dysplasia
• SSLs are precursors to microsatellite unstable (MSI-H) right-sided CRC

6.3 Traditional Serrated Adenoma (TSA)

• Rare (~1% of serrated lesions)
• Predominantly distal colon
• Histology: complex villiform architecture, ectopic crypts with narrow slits, prominent eosinophilic cytoplasm, pencillate (pencil-shaped) nuclei - the defining feature
• Crypts lose their orientation to the muscularis mucosae
• Associated with KRAS or BRAF mutation

6.4 Serrated Polyposis Syndrome (SPS) / Serrated Polyposis

1. ≥20 serrated polyps (any size) spread throughout the colon, OR
2. ≥5 serrated polyps proximal to the sigmoid, with ≥2 measuring >10 mm, OR
3. Any number of serrated polyps with a first-degree relative with SPS

---

7. Hamartomatous Polyps

7.1 Juvenile Polyps

• Most common polyp type in children (but can occur at any age)
• Gross: round, smooth, stalk-bearing, often ulcerated and mucus-filled ("retention cyst")
• Histology: dilated mucous glands in an edematous, inflammatory stroma - the hallmark
• Individual juvenile polyps are not premalignant
• Presentation: rectal bleeding, prolapse, intussusception

• Autosomal dominant; mutations in SMAD4 (50%) or BMPR1A
• Diagnostic criteria: >5 juvenile polyps in colorectum, OR juvenile polyps throughout GI tract, OR any juvenile polyps + family history
• CRC risk: 40% - these lesions CAN degenerate into adenomas and carcinoma
• Screening: start age 10-12 years; annual colonoscopy
• Surgery: total abdominal colectomy + IRA, or proctocolectomy + IPAA if rectum heavily involved

7.2 Peutz-Jeghers Syndrome (PJS)

• Autosomal dominant; LKB1 (STK11) gene mutation
• Hallmarks: GI polyposis (predominantly small intestine > colon) + mucocutaneous melanin pigmentation (lips, buccal mucosa, perioral, hands, feet)
• Histology: arborizing smooth muscle core (branching "arborizing" fronds) covered by normal epithelium - the muscle is the hamartoma
• Complications: intussusception (bowel obstruction), bleeding
• CRC risk: 30-40%
• Extraintestinal malignancies: breast, pancreas, ovary (sex cord tumors with annular tubules), cervix (adenoma malignum), testicle (Sertoli cell tumor)
• Surveillance: baseline colonoscopy + upper endoscopy at age 20 years, then annual flexible sigmoidoscopy

7.3 Cowden Syndrome (PTEN Hamartoma Syndrome)

• Autosomal dominant; PTEN mutation
• Hamartomas of all three embryonal cell layers
• Features: facial trichilemmomas, breast cancer risk, thyroid disease (Lhermitte-Duclos disease of cerebellum), GI polyps
• Bannayan-Riley-Ruvalcaba syndrome is allelic (PTEN)

7.4 Cronkhite-Canada Syndrome

• Non-inherited (sporadic)
• Diffuse GI polyposis (entire tract) + alopecia + nail atrophy/onycholysis + cutaneous hyperpigmentation
• Protein-losing enteropathy, malabsorption, diarrhea, hypogeusia
• High mortality; surgery only for complications

---

8. Inflammatory Polyps (Pseudopolyps)

• Occur most commonly in inflammatory bowel disease (ulcerative colitis, Crohn's disease)
• Represent islands of residual normal/regenerating mucosa surrounded by denuded areas
• Also seen after amoebic colitis, schistosomiasis
• No malignant potential of the polyp itself
• The underlying chronic inflammation (not the polyp) confers CRC risk in IBD

---

9. Malignant Polyp

9.1 Definition

9.2 Haggitt Classification (Pedunculated Polyps)

9.3 Kikuchi Classification (Sessile Polyps)

9.4 Favorable vs. Unfavorable Features (Sleisenger, Table 126.5)

• All favorable features present: Endoscopic polypectomy is curative. No further surgery needed.
• One or more unfavorable features: Adverse outcome risk 10-25% (up to 45-50% with multiple unfavorable features); surgical resection is generally indicated.

---

10. Polyposis Syndromes

10.1 Familial Adenomatous Polyposis (FAP)

• Classic FAP: >100 synchronous colorectal adenomas (can be thousands); polyps in rectum and left colon
• Polyps develop in adolescence; 15% of patients by age 10, 75% by age 20
• Without treatment: 100% CRC risk by age 35-40 (Robbins) / nearly always by age 50
• FAP is at least histologically indistinguishable from sporadic adenomas, though flat/depressed adenomas and microscopic adenomas (1-2 dysplastic crypts) are also prevalent

• Duodenal/periampullary adenomas (>95% of patients) - second leading cause of death in FAP
• Gastric fundic gland polyps (30-90%, low malignant potential)
• Gastric adenomas (10-30%, particularly in Asians)
• Hepatoblastoma

• Epidermoid/sebaceous cysts (~50%)
• Congenital hypertrophy of the retinal pigment epithelium (CHRPE; 75%) - detectable at birth, marker for early screening
• Pilomatrixoma
• Brain tumors (Turcot syndrome variant - medulloblastoma)

• Desmoid tumors (30%) - fibromatosis, may be intraabdominal; can be life-threatening
• Osteomas (80%) - especially mandible
• Dental abnormalities

• Gardner Syndrome: FAP + osteomas + desmoid tumors + soft tissue tumors (specific APC mutation)
• Turcot Syndrome: FAP + CNS malignancy (medulloblastoma); also seen with Lynch syndrome (glioblastoma)
• Attenuated FAP (AFAP): <100 adenomas; right colon predominance; APC mutation outside codons 168-1640; later onset; CRC risk still ~100% but delayed

1. Restorative proctocolectomy + IPAA (ileal pouch-anal anastomosis): Removes all colorectal mucosa; preferred for dense rectal polyposis; preserves continence; ~10% pouch failure rate; still requires surveillance of "rectal cuff" if stapled anastomosis
2. Total colectomy + IRA (ileorectal anastomosis): Preserves rectum; suitable if <20 rectal polyps; rectum requires annual endoscopic surveillance; 10% develop rectal cancer
3. Total proctocolectomy + end ileostomy: For patients who cannot undergo IPAA or where continence is not possible

10.2 MUTYH-Associated Polyposis (MAP)

• Autosomal recessive - key distinction from FAP
• Biallelic mutation of base-excision repair gene MUTYH (MYH)
• <100 polyps; later onset than FAP
• Sessile serrated polyps, hyperplastic polyps, often with KRAS mutations
• CRC risk: ~80%

10.3 Lynch Syndrome (HNPCC)

• Autosomal dominant; mutations in MMR genes: MLH1, MSH2 (most common), MSH6, PMS2
• Not a true polyposis (few polyps), but markedly accelerated adenoma-to-carcinoma sequence
• Right-sided predominance; mucinous/signet ring histology; MSI-H tumors; better prognosis
• Amsterdam II criteria and revised Bethesda guidelines used for identification
• CRC risk: ~50-80%; also endometrial, ovarian, gastric, urinary tract, biliary cancers
• Surveillance: colonoscopy every 1-2 years from age 20-25 years

---

11. Risk Factors for Colorectal Polyps

• Age - most important determinant; risk increases steeply after age 50
• Male sex - RR ~1.5 vs women; men aged 45-49 have similar advanced adenoma prevalence as women aged 55-59
• Family history - first-degree relative with CRC/adenoma doubles risk
• Race - African Americans and Hispanics have greater proportion of proximal adenomas

• Low dietary fiber, high red/processed meat intake, high fat
• Obesity, physical inactivity - independently increase risk
• Smoking - strongly associated with serrated polyps and HP polyposis
• Alcohol - dose-dependent risk
• Diabetes/metabolic syndrome - increased risk via insulin resistance

• NSAIDs/Aspirin (most well-established): >110 animal studies + >35 epidemiologic studies confirm 25-35% reduction in adenoma risk via COX-2 inhibition → reduced cellular proliferation, enhanced apoptosis, reduced angiogenesis
• 81 mg/day aspirin reduces RR of adenoma and advanced adenoma by 19% and 41% respectively (Sleisenger)
• Calcium supplements (modest effect)
• Hormone replacement therapy (HRT) in postmenopausal women
• Selenium
• Physical activity, weight loss

---

12. Clinical Presentation

• Rectal bleeding - most common symptom (usually occult, detected on FOBT/FIT)
• Change in bowel habit - especially with large polyps
• Mucous secretion - especially villous adenomas; massive secretion (>3 L/day) causing dehydrating diarrhea = McKittrick-Wheelock syndrome
• Iron-deficiency anemia - from chronic occult blood loss
• Rarely: obstruction, intussusception (hamartomatous polyps in children), prolapse

---

13. Diagnosis

13.1 Colonoscopy

• Gold standard - detects and allows simultaneous removal
• Sensitivity: ~94% for polyps >10 mm; lower for flat/sessile lesions
• Reports polyp number, size, location, morphology (Paris classification)

13.2 Chromoendoscopy & Advanced Imaging

• NBI (narrow band imaging): Enhances vascular patterns; NICE classification (type 1 = hyperplastic, type 2 = adenoma)
• Kudo pit pattern: Type I/II = non-neoplastic; III-V = neoplastic; requires chromoendoscopy and high-magnification (100x)
• FICE, i-SCAN, linked color imaging (LCI): Enhanced imaging for improved adenoma detection rate (ADR)

13.3 CT Colonography (Virtual Colonoscopy)

• Sensitivity: 92% for polyps ≥10 mm; 78-86% for polyps 5-9 mm; poor for <5 mm
• Cannot biopsy/resect; detects incidental extracolic findings (up to 70% of cases; 11% clinically significant)
• Management of 6-9 mm polyps found on CTC remains debated

13.4 Stool Tests

• FIT: Sensitivity ~60-79% for adenomas; widely used for population screening
• Cologuard (multi-target stool DNA): Sensitivity 92% for CRC, but only ~42% for advanced adenomatous polyps
• Stool tests do not detect/remove polyps; positive result requires colonoscopy

---

14. Management

14.1 Polypectomy Techniques

• Cold snare polypectomy: Preferred for polyps <10 mm (no electrical current; lower delayed bleeding rate)
• Hot snare polypectomy: Larger polyps (10-19 mm); uses electrocautery
• EMR (Endoscopic Mucosal Resection): For sessile polyps ≥20 mm; submucosal saline injection to "lift" lesion before snare resection; piecemeal removal acceptable but reduces histologic staging ability
• ESD (Endoscopic Submucosal Dissection): En-bloc removal of large lesions; superior for staging malignant polyps; technically demanding
• Tattoo marking of sessile polypectomy sites - essential for subsequent endoscopic surveillance and surgical localization
• Argon plasma coagulation (APC): Adjunctive ablation of residual adenomatous tissue at polypectomy margins; not suitable as primary treatment (no specimen obtained)

14.2 Complications of Polypectomy

• Bleeding (most common): Usually immediate but can be delayed up to 2 weeks; self-limiting in most; managed with endoscopic clips, epinephrine injection, resnaring, APC; rarely requires angiography or surgery
• Perforation: Microperforation in a prepared patient - bowel rest + broad-spectrum antibiotics + observation; signs of sepsis/peritonitis = laparotomy
• Post-polypectomy syndrome: Transmural burn without free perforation; localized pain + fever after polypectomy; managed conservatively

14.3 Malignant Polyp Management

• Complete en-bloc endoscopic excision + histopathologic assessment
• If all favorable features: no further surgery
• If unfavorable features (poor differentiation, vascular invasion, involved margin, deep SM invasion): surgical resection
• Sessile malignant rectal polyps: consider full-thickness surgical excision (TAE, TEM, TAMIS) ± adjuvant chemoradiation for high-risk cases
• Re-colonoscopy at 3-6 months after large polyp removal to confirm completeness

---

15. Surveillance After Polypectomy

---

16. Chemoprevention

---

17. Pro-Level Molecular Summary Table

---

18. Key Numbers to Memorize (Exam & Clinical Practice)

---

Recent Guidelines Update

• AGA 2023 Post-Polypectomy Surveillance Update [PMID 37737817]: Updated risk stratification for post-polypectomy surveillance now incorporates serrated lesion features; patients with SSLs ≥10 mm or with dysplasia are now explicitly placed in the high-risk (3-year interval) category.
• EHTG-ESCP 2024 FAP/MAP Guidelines [PMID 38722804]: Updated European guidelines for management of adenomatous polyposis syndromes including FAP, MAP, and GAPPS; emphasizes individualized surgical approach and endoscopic surveillance protocols.
• AGA Living CPG on Computer-Aided Detection (CADe) Colonoscopy [PMID 40121061]: AI-assisted colonoscopy modestly but significantly increases adenoma detection rate (ADR); now endorsed as an adjunct in routine colonoscopy.

---

• Schwartz's Principles of Surgery, 11e (Chapter on Colorectal Polyps)
• Sleisenger & Fordtran's GI and Liver Disease, Chapter 126 (Colonic Polyps and Polyposis Syndromes)
• Yamada's Textbook of Gastroenterology, 7e, Chapter 70
• Bailey & Love's Short Practice of Surgery, 28e, Chapter 77
• Robbins & Kumar Basic Pathology / Robbins Cotran & Kumar Pathologic Basis of Disease, Chapter 17
• Current Surgical Therapy, 14e (Colorectal Polyps chapter)